Abstract
The formation of a tumor-associated vascular network is an important step in understanding the stages of tumor progression. This review aims to highlight the main markers of induction, proliferation and inhibition of angiogenesis, as well as the quantification of microvessel density, correlated with preclinical and clinical research in gynecologic cancers and also discussed related patents. Studies show that in the most advanced cases of gynecological cancers, biomarkers such as VEGF (Vascular Endothelial Growth Factor), MMP (Matrix Metalloproteinase), CD105 (Endoglin), TIMP (tissue inhibitors of metalloproteinases) and VASH (Vasohibin) are more expressed compared to healthy individuals. Continuous evaluation of these biomarkers in cancer cases could serve in the future as a basis for development of new therapeutic approaches, leading to a good response to cancer treatment, and thus increase survival of cancer patients.
Keywords: Angiogenesis, biomarkers, endoglin, gynecologic cancer, microvessel density, VEGF.
Recent Patents on Anti-Cancer Drug Discovery
Title:Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review
Volume: 10 Issue: 3
Author(s): Douglas R. Abdalla, Cindy Simoens, John-Paul Bogers, Eddie F.C. Murta and Marcia A. Michelin
Affiliation:
Keywords: Angiogenesis, biomarkers, endoglin, gynecologic cancer, microvessel density, VEGF.
Abstract: The formation of a tumor-associated vascular network is an important step in understanding the stages of tumor progression. This review aims to highlight the main markers of induction, proliferation and inhibition of angiogenesis, as well as the quantification of microvessel density, correlated with preclinical and clinical research in gynecologic cancers and also discussed related patents. Studies show that in the most advanced cases of gynecological cancers, biomarkers such as VEGF (Vascular Endothelial Growth Factor), MMP (Matrix Metalloproteinase), CD105 (Endoglin), TIMP (tissue inhibitors of metalloproteinases) and VASH (Vasohibin) are more expressed compared to healthy individuals. Continuous evaluation of these biomarkers in cancer cases could serve in the future as a basis for development of new therapeutic approaches, leading to a good response to cancer treatment, and thus increase survival of cancer patients.
Export Options
About this article
Cite this article as:
Abdalla R. Douglas, Simoens Cindy, Bogers John-Paul, Murta F.C. Eddie and Michelin A. Marcia, Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review, Recent Patents on Anti-Cancer Drug Discovery 2015; 10 (3) . https://dx.doi.org/10.2174/1574892810999150827153642
DOI https://dx.doi.org/10.2174/1574892810999150827153642 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of P2X3 Receptor Structure and Function
CNS & Neurological Disorders - Drug Targets γ-Hydroxybutenolide Containing Marine Natural Products and Their Synthesis: A Review
Current Organic Chemistry Interaction and Cytotoxic Effects of Hydrophobized Chitosan Nanoparticles on MDA-MB-231, HeLa and Arpe-19 Cell Lines
Current Topics in Medicinal Chemistry Review of the Phytochemistry and Biological Activity of Cissus incisa Leaves
Current Topics in Medicinal Chemistry Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Patented Bioavailability Enhancement Techniques of Silymarin
Recent Patents on Drug Delivery & Formulation Recent Advances in Chalcone-Based Anticancer Heterocycles: A Structural and Molecular Target Perspective
Current Medicinal Chemistry Synthesis and Biological Activity of Some New N1-(6-fluoro-4-oxoquinolin- 8-yl)amidrazones
Letters in Organic Chemistry Kaempferol-3-<i>O</i>-Rhamnoside Inhibits the Proliferation of Jurkat Cells Through Jun Amino-Terminal Kinase Signaling
The Natural Products Journal Lactoferrin as a Natural Immune Modulator
Current Pharmaceutical Design Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Role of the Retinoblastoma Tumor Suppressor in the Maintenance of Genome Integrity
Current Molecular Medicine Synthesis, Characterization by Means of IR, 1H, 13C - NMR and Biological Investigations on New Diorganotin Carboxylic Acid Derivatives
Letters in Drug Design & Discovery Prediction of MicroRNA–disease Associations by Matrix Completion
Current Proteomics β-Catenin/TCF-4 Signaling Regulates Susceptibility of Macrophages and Resistance of Monocytes to HIV-1 Productive Infection
Current HIV Research Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase
Anti-Cancer Agents in Medicinal Chemistry Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines
Current Topics in Medicinal Chemistry The Functions of Histone Modification Enzymes in Cancer
Current Protein & Peptide Science Immune Checkpoint Inhibitors in the Treatment of Cancer
Current Reviews in Clinical and Experimental Pharmacology